✦ LIBER ✦

Improved survival after one course of perioperative chemotherapy in early breast cancer patients: long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854

✍ Scribed by J.A van der Hage; C.J.H van de Velde; J.-P Julien; J.-L Floiras; T Delozier; C Vandervelden; L Duchateau

Book ID: 117657391
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 174 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)00294-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Doxorubicin-paclitaxel : A safe regimen

Doxorubicin-paclitaxel : A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial

✍ Laura Biganzoli; Tanja Cufer; Peter Bruning; Robert E. Coleman; Luc Duchateau; B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Abstract ## BACKGROUND The potential cardiotoxicy of the doxorubicin‐paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies. ## METHODS In a large multicenter Phase III

After 10 years of follow-up, preoperativ

After 10 years of follow-up, preoperative chemotherapy is still safe in operable breast cancer: Clinical and translational results from the European Organisation for Research and Treatment of Cancer Trial 10902

✍ J.G.H. Van Nes; Van der Hage; J. Bogaerts; I. Delmotte; M. De Vos; P. Therasse; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Decreased immunoreactivity for p27 prote

Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status : Results from International Breast Cancer Study Group Trial V

✍ Vito J. Spataro; Heather Litman; Giuseppe Viale; Fausto Maffini; Michele Masullo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to clarify the prognostic and predictive value of immunoreactivity for the cyclin‐dependent kinase inhibitor p27(Kip1) in patients with early‐stage breast carcinoma and to investigate its relation with clinicopathologic features and other m

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Commentary on “International phase III t

Commentary on “International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial.” Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, and the International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. Medical Research Council Clinical Trials Unit, London, United Kingdom: J Clin Oncol 2011;29:2171–7

✍ H. Barton Grossman 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB